Who are Steris’s competitors?
Steris names 21 companies as competitors in its latest annual report, on 4 fronts.
Skip to the field, head to head ↓Steris company profile
Steris names 21 rivals across four lists, and none appears on all four
Steris sorts its competitors into four groups: products, services, sterilization and infection prevention, and contract sterilization. The groups barely overlap. Belimed, Ecolab and Getinge appear in two. So does Olympus. No one appears in three. Contract sterilization names Sterigenics alone.
So the only name on every list is Steris. Each rival meets it on one front or two, while Steris meets all of them. The rivals also look unlike one another. Stryker reported revenue of $25.1 billion and Fortive $4.2 billion. Ecolab paid $1.6 billion in cash for Ovivo's electronics business. Boston Scientific bought Apollo Endosurgery and Relievant Medsystems. Their money is going in different directions.
Steris brought in $5.9 billion, grew 9% and kept a 13% net margin. The idea to repeat: Steris's position is its breadth. Each rival contests a piece of it, and Steris has to defend the whole.
Where Steris says it competes
“On a product basis, competitors include 3M, Baxter, Boston Scientific, Belimed, Ecolab, Fortive, Getinge, Karl Storz, Olympus, Ruhof, SteelCo, Stryker, Skytron and Wassenburg.”
“competitors include BBraun, Crothall, Olympus and Pentax”
“Competitors include Belimed, Contec, Ecolab, Fedegari, Getinge, and Stilmas.”
“competes with Sterigenics, other smaller contract sterilization companies”
The field, from the filings
| Company | Fiscal year | Revenue | Growth | Net margin | Employees |
|---|---|---|---|---|---|
| Steris | FY to Mar 2026 | $5.9B | +9% | 13% | 18,000 |
| Stryker | 2025 | $25.1B | +11% | 13% | 56,000 |
| 3M | 2025 | $24.9B | +2% | 13% | – |
| Boston Scientific | 2025 | $20.1B | +20% | 14% | 59,000 |
| Ecolab | 2025 | $16.1B | +2% | 13% | – |
| Baxter International | 2025 | $11.2B | +6% | −9% | – |
| Fortive | 2025 | $4.2B | +2% | 14% | – |
Each company’s latest fiscal year as reported to the SEC, in US dollars; fiscal years end in different months. Rivals that report outside the US or in other currencies are not shown.
What the rivals have done lately
“On May 2, 2023 we acquired Cerus for net cash consideration of $ 289 and up to $ 225 in future milestone payments that had a fair value of $ 192 at the acquisition date.” filing
“In the second quarter of 2023, we completed the acquisition of Apollo Endosurgery, Inc., a public company that has developed and commercialized endoscopic suturing devices including OverStitch™ Endoscopic Suturing Systems and X-Tack™ End…” filing
“In addition, in the fourth quarter of 2023, we completed the acquisition of Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept™ Intraosseous Nerve Ablation System, …” filing
“On December 16, 2025, we acquired Ovivo’s electronics business (“Ovivo Electronics”) for total consideration of $1.6 billion in cash.” filing
“Under the terms of the acquisition, we paid the acquisition price of $122 million and received specified intellectual property, including patent rights, in the first quarter of 2022 and received additional intellectual property, includin…” filing
Asked about Steris’s competitors
Who are Steris's competitors?
In its annual report for fiscal 2026, Steris names 21 competitors across 4 fronts: product-based competitors, service line competitors, competitors in sterilization and infection prevention and contract sterilization competitors. 10-K for fiscal 2026
How does Steris compare with its rivals?
Steris reported $5.9B in revenue in its latest fiscal year, +9% on a year, with a 13% net margin. Ecolab: $16.1B, 13% net margin; Stryker: $25.1B, 13% net margin.
What are the alternatives to Steris?
The companies Steris itself names as competitors are listed above, front by front, each in its own report’s words. Which matters for a given buyer depends on the job, not the list.
What would it actually cost a challenger to take your customer?
Sources: Steris’s annual report for fiscal 2026; the annual reports of the companies that name it; each company’s financial data as reported to the SEC; Stratrix Decision Records. Analysis and data, not advice.
For information and strategic analysis only, not investment advice. Stratrix does not recommend buying, selling or holding any security.
Tools to try
- Ansoff move finderFramework: Ansoff Matrix
- Business model canvas builderFramework: Business Model Canvas
- Change readiness checkFramework: Kotter's 8-Step Change Model
- Five Forces scorerFramework: Porter's Five Forces
- SMART goal builderFramework: SMART Goals
- SWOT builderFramework: SWOT Analysis
More from Stratrix
The Moat Anatomy Casebook
Every verified case of this decision, with what was on the table and how it turned out, in Excel, PowerPoint, Word and PDF.
35 verified cases · $299See the casebook →The Business Model Wizard
Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.
Free · about twelve minutesBuild your Model Thesis →Weekly email
Stratonomics, every Tuesday
One data story every Tuesday: what happened, what it means, and the figures you can quote. Free.